Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 8Gastrointestinal 3Dermatologic 3Other 2Lymphoid 2Genitourinary 2Thoracic 1Other neoplasm 1Other hematologic neoplasm 1

Conditions

Melanoma 2Skin Neoplasms 1Dermatitis, Contact 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Docosahexaenoic Acids × Dermatologic × Clear all
NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

NCT01032343 2013-08-22

An Immunonutritional Approach to the Prevention of Skin Cancer

University of Manchester

Phase NA Completed
90 enrolled
Dermatologic

Dermatitis, Contact, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡